Skip to content
777 Sourcing.

Capability

complement C3 targeted therapy development

Suppliers
1
States & provinces
1
Countries
1

1 complement c3 targeted therapy development supplier across 1 states and provinces in 1 country. Profiles show capabilities, materials, certifications, and facility locations so you can compare shops and build a shortlist.

Suppliers

APL SALES I LLC

WALTHAM, MA

Apellis Pharmaceuticals is a biopharmaceutical company that develops therapies targeting C3 to treat diseases driven by excessive activation of the complement cascade, including in hematology, ophthalmology, and nephrology. Its focus areas include geographic atrophy and rare disease. Apellis has been acquired by Biogen.

biopharmaceutical researchclinical trials

Compiled from public sources

Related capabilities

Other processes offered by the shops that list complement C3 targeted therapy development.

Browse all capabilities